Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?

Claudia Marchetti¹, Andrea Rosati^{1

2}, Giovanni Scambia^{1

2}, Anna Fagotti^{1

2}

Affiliations

¹ Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Catholic University of the Sacred Heart, Rome, Italy.

Editorial

Claudia Marchetti et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S372.

doi: 10.21037/atm.2019.12.94.

Claudia Marchetti¹, Andrea Rosati^{1

2}, Giovanni Scambia^{1

2}, Anna Fagotti^{1

2}

¹ Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Catholic University of the Sacred Heart, Rome, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA. Gockley A, et al. Am J Obstet Gynecol. 2019 Dec;221(6):625.e1-625.e14. doi: 10.1016/j.ajog.2019.06.009. Epub 2019 Jun 14. Am J Obstet Gynecol. 2019. PMID: 31207237

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
1. Pisano C, Bruni GS, Facchini G, et al. Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag 2009;5:421-6. - PMC - PubMed
1. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154-64. 10.1056/NEJMoa1611310 - DOI - PubMed
1. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1274-84. 10.1016/S1470-2045(17)30469-2 - DOI - PubMed
1. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1949-61. 10.1016/S0140-6736(17)32440-6 - DOI - PMC - PubMed